NewAmsterdam Pharma
Clinical-stage biopharmaceutical company developing oral, non-statin therapies for patients at risk of cardiovascular disease with elevated LDL-cholesterol, particularly focusing on CETP inhibition.
Location
Naarden, Netherlands
Founded
2019
Categories
biotech, cardiovascular, lipid-disorders, pharmaceuticals
Notes
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with cardiovascular disease who have elevated LDL-cholesterol. The company's lead product candidate is obicetrapib, an oral CETP (cholesteryl ester transfer protein) inhibitor that has shown significant LDL-cholesterol lowering in clinical trials.
The company went public on NASDAQ (ticker: NAMS) through a SPAC merger with Frazier Lifesciences Acquisition Corporation in 2022.
Team
- Michael Davidson, M.D. - Chief Executive Officer
- LinkedIn: linkedin.com/in/michaeldavidsonmd
- John Kastelein, M.D., Ph.D. - Co-Founder & Chief Scientific Officer
- Daniel O'Day - Board Member
Additional Research Findings
- Listed on NASDAQ (NAMS) since November 2022
- Headquarters in Naarden, Netherlands with operations in US
- Lead candidate: obicetrapib - oral CETP inhibitor for LDL-cholesterol reduction
- Targeting patients with familial hypercholesterolemia and those intolerant to statins
- Backed by Bain Capital Life Sciences, Forbion, and other major healthcare investors
- Completed Phase 3 trials showing 50%+ reduction in LDL-cholesterol
- Non-statin approach provides alternative for statin-intolerant patients